Views: 0 Author: Site Editor Publish Time: 2022-10-05 Origin: Site
Early results are from South Africa, and these reports show more consistently that Omicron infection leads to lower hospitalization rates than Delta mutant infection.
On 14 December, Discovery Healthy, a South African insurance company, based on 78,000 omicron-positive people, showed a 
29% lower risk of hospitalization in those infected with Omicron compared with those infected with other mutants.
This is the most important data available on omicron-infected hospitalization rates.
However, some researchers say it is too early to draw conclusions, as key methodological details for this figure have not yet been published, and hospitalization rates are affected by hospital capacity, age of the infected person, and pre-infection specific immunity status (vaccination and COVID-19 infection, etc.). But Waasila Jassat of South Africa's National Institute of Infectious Diseases says the results are similar to other studies in the country. Although this data set may be flawed, different studies show consistent results.
At least in the real world in South Africa, the current rate of omicron-infected patients being hospitalized is actually lower.
On December 13th Data released in Denmark showed that people infected with Omicron were admitted to hospital at rates comparable to those infected with other strains. A total of 3,400 Omicron infections were found in Denmark, of which 37 were hospitalized [1]. The group's flaws were also clear: too few cases.
On 16 December, research at Imperial College London, UK showed no evidence of fewer hospitalizations due to Omicron infection compared to the Delta mutant.
Those infected with Omicron do not experience the loss of smell, high fever or breathing difficulties characteristic of previous strains, but instead develop relatively mild symptoms such as cough, fatigue, nasal congestion or runny nose that are hard to distinguish from flu or even the common cold, all adding to the difficulty of prevention.
Both the ultimate severity of Omicron infection and the social/medical stress caused by its high infectivity and immune escape ability make it likely that Omicron will again cause serious harm to humans.
Henan UDX Biotechnology Co, Ltd is a professional high-tech biotechnology company who is engaged in R&D, manufacturing and marketing for medical in-vitro diagnostic(IVD) rapid test kits , like covid-19 antigen rapid test kit, covid-19 Ig/G, Ig/M rapid test kit, total antibodies rapid test kit and covid-19 antigen&saliva rapid test kit and so on.
UDXBIO is focus on the development of Testing Solutions for the SARS-CoV-2. And can test the new mutant of Omicron according to it’s test theory.
Our founder has been in the biotechnology field for almost 30 years. The R&D VP has a strong medical technical background who got the PhD. from Ivy League prestigious school, published heavyweight papers in internationally renowned journals for many times.
Now we cooperate with R&D institutions and universities in the United States and UK who can offer the strongest medical technical support for the development of the company. Our producing management team has more than 20 years producing experience of in-vitro diagnostic(IVD)rapid test kits.
With an area of about 10000 square meters, UDXBIO currently has about over 300 employs, among them more than 60 people are Masters and PhD. degree, and more than 20 workers are senior technical.
Producing according to the standard of ISO 13485, UDXBIO has established rigorous productive process and complete quality management system to ensure that all products are good quality under the strict and efficient management process.
We have established solid business relationships with over 50 countries through our brand UDXBIO Rapid test as well as OEM packing. Our business is booming, we are thrilled to find distributors and OEM partners worldwide for mutual success.
